Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment
Background Cancer cachexia is a debilitating, wasting condition that affects many cancer patients, including those with head and neck cancer. The overall incidence of cancer cachexia is quite high for some types of cancer, and cachexia will be the main cause of death for more than 20% of all cancer...
Saved in:
Published in | Head & neck Vol. 29; no. 4; pp. 401 - 411 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.04.2007
John Wiley & Sons |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Cancer cachexia is a debilitating, wasting condition that affects many cancer patients, including those with head and neck cancer. The overall incidence of cancer cachexia is quite high for some types of cancer, and cachexia will be the main cause of death for more than 20% of all cancer patients. This syndrome uniquely challenges patients with head and neck cancer. This article outlines the diagnosis of cancer cachexia, reviews its impact on patient quality of life (QOL) and survival, and updates the reader on potential therapies that may suppress it.
Methods
A comprehensive literature search was performed using PubMed of the National Library of Medicine, which includes more than 15 million citations back to the 1950s. The Cochrane Library and Google search engine were used as well.
Results
This syndrome differs significantly from starvation, and thus accurate and timely diagnosis is essential. Nutritional therapy alone is insufficient. Current management strategies include corticosteroids and megesterol acetate, in conjunction with nutritional therapy. Future strategies may include nutraceuticals, omega‐3 fatty acids, inflammatory antagonists, and other targeted treatments.
Conclusions
Because cancer cachexia differs significantly from starvation, nutritional supplementation must be used in conjunction with other anti‐cachexia agents to reverse the chronic systemic inflammatory state and the effects of circulating tumor‐derived factors seen in cachexia. Careful identification of patients at risk and those suffering from this syndrome will lead to better outcomes and treatments. Ultimately, more research is needed to better treat this devastating condition. © 2007 Wiley Periodicals, Inc. Head Neck, 2007 |
---|---|
Bibliography: | ark:/67375/WNG-H0TRZH5L-2 Doris Duke Clinical Research Fellowship Program istex:280125DA3A0289A2C6D218320683E92A31E0056E ArticleID:HED20447 Supported by grant RR000046 from the University of North Carolina General Clinical Research Center ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 1043-3074 1097-0347 |
DOI: | 10.1002/hed.20447 |